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Summary
Background To effectively prevent, detect, and treat health conditions that affect people during their lifecourse, health-care 
professionals and researchers need to know which sections of the population are susceptible to which health conditions 
and at which ages. Hence, we aimed to map the course of human health by identifying the 50 most common health 
conditions in each decade of life and estimating the median age at first diagnosis.
Methods We developed phenotyping algorithms and codelists for physical and mental health conditions that involve 
intensive use of health-care resources. Individuals older than 1 year were included in the study if their primary-care 
and hospital-admission records met research standards set by the Clinical Practice Research Datalink and they had 
been registered in a general practice in England contributing up-to-standard data for at least 1 year during the study 
period. We used linked records of individuals from the CALIBER platform to calculate the sex-standardised 
cumulative incidence for these conditions by 10-year age groups between April 1, 2010, and March 31, 2015. We also 
derived the median age at diagnosis and prevalence estimates stratified by age, sex, and ethnicity (black, white, south 
Asian) over the study period from the primary-care and secondary-care records of patients.
Findings We developed case definitions for 308 disease phenotypes. We used records of 2 784 138 patients for the 
calculation of cumulative incidence and of 3 872 451 patients for the calculation of period prevalence and median age at 
diagnosis of these conditions. Conditions that first gained prominence at key stages of life were: atopic conditions and 
infections that led to hospital admission in children (<10 years); acne and menstrual disorders in the teenage years 
(10–19 years); mental health conditions, obesity, and migraine in individuals aged 20–29 years; soft-tissue disorders and 
gastro-oesophageal reflux disease in individuals aged 30–39 years; dyslipidaemia, hypertension, and erectile dysfunction 
in individuals aged 40–59 years; cancer, osteoarthritis, benign prostatic hyperplasia, cataract, diverticular disease, type 2 
diabetes, and deafness in individuals aged 60–79 years; and atrial fibrillation, dementia, acute and chronic kidney 
disease, heart failure, ischaemic heart disease, anaemia, and osteoporosis in individuals aged 80 years or older. Black or 
south-Asian individuals were diagnosed earlier than white individuals for 258 (84%) of the 308 conditions. Bone 
fractures and atopic conditions were recorded earlier in male individuals, whereas female individuals were diagnosed at 
younger ages with nutritional anaemias, tubulointerstitial nephritis, and urinary disorders.
Interpretation We have produced the first chronological map of human health with cumulative-incidence and period-
prevalence estimates for multiple morbidities in parallel from birth to advanced age. This can guide clinicians, policy 
makers, and researchers on how to formulate differential diagnoses, allocate resources, and target research priorities 
on the basis of the knowledge of who gets which diseases when. We have published our phenotyping algorithms on 
the CALIBER open-access Portal which will facilitate future research by providing a curated list of reusable case 
definitions.
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Engineering and Physical Sciences Research Council, National Institute for Social Care and Health Research, and 
The Alan Turing Institute.
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Introduction
A chronological map of human health from birth to death 
depicting the most common conditions by age and 
marking the median age at diagnosis is fundamental to 
understanding who gets which conditions when, on a 
population level. This understanding can inform clinicians 
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about the frequency, and hence the prior probability, of a 
range of conditions on the basis of the age of presentation. 
This knowledge could also allow policy makers to consider 
common conditions at different ages or in different groups 
when allocating training and resources, and researchers 
and their funders to prioritise prevalent conditions.
Research in context
Evidence before this study
We did two English language searches in MEDLINE for studies 
published in the past 10 years: one search for studies describing 
disease prevalence for multiple diseases, using the keywords 
“diseases” OR “disorders”, “epidemiology” OR “prevalence”, AND  
“comorbidity” OR “multimorbidity”; and the other for studies 
reporting mean or median age of disease onset or diagnosis 
using the keywords “diseases” OR “disorders”, AND “age of 
onset” OR “age at diagnosis” OR “age of diagnosis”, AND “mean” 
OR “median”.
Consented cohort studies investigating multiple health 
conditions were limited in age range and in ascertainment of 
conditions diagnosed in primary care. Many had too few 
participants to reliably estimate disease distribution by age, sex, 
and ethnicity. Studies based on electronic health records (EHRs) 
surmounted these limitations, but the manual curation 
required for developing case definitions and phenotype 
algorithms from EHR data restricted the number of conditions 
analysed within a single study to fewer than 100. Many studies 
reported prevalence estimates for comorbid conditions relative 
to an index disease, such as heart failure. Some were confined 
to either primary or secondary care. The Global Burden of 
Disease initiative inferred disease prevalence estimates from 
mathematical models based on empirical frequency data. The 
US National Cancer Institute’s Surveillance, Epidemiology, and 
End Results cancer statistics review reported age at diagnosis by 
sex and ethnicity for primary cancer sites. Most other studies 
reported age at diagnosis for a single disease from small, 
sometimes unrepresentative sample sets. We did not find any 
studies that described the age distribution and age at diagnosis 
stratified by sex and ethnicity from birth to death for several 
hundred diseases contemporaneously with a single linked 
clinical dataset obtained from primary-care and secondary-care 
settings within a universal health-care system.
Added value of this study
We present the first lifecourse map of human health, charting 
the 50 most common conditions in each decade of life, and the 
median age at diagnosis for 308 conditions. We compiled case 
definitions, cumulative incidence and age-specific, sex-specific 
and ethnicity-specific period prevalences for 308 conditions, by 
harmonising Read, International Classification of Diseases 
(tenth revision), and Office of the Population Censuses and 
Surveys Classification of Interventions and Procedures version 4 
codes across primary-care and secondary-care records in 
England. This has involved updating and extensively expanding 
the phenotyping algorithms in the CALIBER Portal. Conditions 
were selected to reflect the disease burden and health-care 
utilisation of the English population, which are likely to be 
similar to those in countries with similar economies and 
population structures. Conditions with more than 
10 000 Hospital Episode Statistics finished consultant episodes 
(the time spent under the care of one consultant while 
admitted to hospital) in England from April 1, 2014, to 
March 31, 2015, or those with estimated prevalences greater 
than 0·01% and considered clinically important by our panel of 
clinicians were included in this report.
Our results illustrate the varying dominance of different 
conditions through the passage of life. Common childhood 
conditions were atopic disorders and acute infections. Acne and 
menstrual disorders gained prominence in teenagers. Mental 
health disorders emerged in young adults, together with 
obesity and migraine. Disorders associated with the metabolic 
syndrome, soft tissue disorders, erectile dysfunction, and 
gastro-oesophageal reflux disease rose substantially in 
middle-age. Cancer, osteoarthritis, benign prostatic hyperplasia, 
cataract, diverticular disease, and deafness became more 
common in individuals aged 60–79 years, whereas atrial 
fibrillation, dementia, acute and chronic kidney disease, heart 
failure, ischaemic heart disease, anaemia, and osteoporosis 
escalated in advanced age (≥80 years).
Ethnic and sex differences were also discernible. White patients 
had later median age at diagnosis for 258 of the 
308 conditions. Although this could be attributed to the older 
age structure of the white population, another potential reason 
is that distinct biological pathways can lead to the same 
diagnosis in different demographic groups. Sleep apnoea, for 
example, was common in black boys and older white men, with 
potentially different mechanisms underlying the two groups. 
Female individuals were younger at diagnosis of 
tubulointerstitial nephritis, urinary incontinence, chronic 
cystitis, and nutritional anaemias, whereas male individuals 
were diagnosed at younger ages with bone fractures and atopic 
conditions.
Implications of all the available evidence
By mapping the distribution of health conditions across the 
lifecourse, we have empowered researchers, clinicians, 
health-care providers, and policy makers to better identify 
individuals at risk, and to instigate strategies to detect, prevent, 
and manage specific conditions. The patterns of disease 
distribution that we have revealed could lead to further 
research into the heterogeneous causes of diseases. The 
platform that we have created can promote further research 
into ageing-related health conditions and multimorbidity to 
meet the challenges facing ageing populations. By providing 
the phenotyping algorithms for hundreds of conditions 
through an existing open access Portal (CALIBER), we are also 
facilitating the use of EHR data in large cohort studies such as 
UK Biobank in this era of high-throughput biomedical data.
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Addressing this question requires large-scale, 
population-based studies with broad coverage of health 
conditions and appropriate age-related frequency 
measures. The age-specific cumulative incidence estab-
lishes when specific conditions are more likely to occur 
during the lifecourse, while the age-specific period 
prevalence unveils the collective past medical history of a 
population at each stage of life over a specified calendar 
time period. Age at first recorded diagnosis by sex and 
ethnicity characterises patterns of health-condition onset 
by age and differences between demographic groups, 
with potentially distinctive underlying pathological 
processes. Although the Global Burden of Disease (GBD) 
reports1 and multimorbidity studies2,3,4 have drawn from 
various data sources to estimate disease frequency 
statistics for the overall population, there have been no 
previous studies linking prevalence estimates with age of 
diagnosis for multiple conditions in parallel within a 
single health system, to draw the chronological map of 
human health conditions across the lifecourse.
The UK National Health Service (NHS) is well placed to 
support these analyses, as the provider of universal 
cradle-to-grave health care in the UK since 1948, with 
more than 98% of the UK population registered with an 
NHS general practice.5 NHS clinical data can be 
aggregated on a population scale, with electronic health 
records (EHRs) in primary care6 linked to digitised 
disease-episode coding in secondary care7 using unique 
NHS identification numbers assigned permanently to 
individuals.8 EHRs comprise data from multiple sources 
with a variety of coding schemes, wherein a single 
condition such as type 2 diabetes might be represented by 
hundreds of codes. Therefore, the construction of case 
definitions and codelists across the various clinical 
settings requires meticulous curation, which has 
previously been a limiting factor in the contemporaneous 
study of hundreds of conditions.
We have created a chronological map of human health 
by charting the most common mental and physical health 
conditions by decade of age, and by estimating the median 
age at first recorded diagnosis for 308 health conditions 
using linked EHRs in England. We have also compiled a 
compendium of phenotyping algorithms and codelists; 
age-specific, sex-specific, and ethnicity-specific 
prevalences; and median age at first record by sex and 
ethnicity of the spectrum of disorders affecting recipients 
of NHS care for the use of clinicians, policy makers, 
health-care providers, and researchers.
Methods
Study design and participants
We studied population-based EHRs of primary-care 
patient-level data from the Clinical Practice Research 
Datalink (CPRD) linked to the dataset of the Hospital 
Episode Statistics (HES) for admitted-patient care. CPRD 
is one of the largest EHR databases in the world, is 
representative of the English population by age, sex, and 
ethnicity,5,9 provides anonymised data, and has been 
previously validated for epidemiological research.10 
Individuals older than 1 year were included in the study if 
their records met research standards set by the CPRD5 
and they had been registered in a general practice in 
England contributing up-to-standard data for at least 
1 year from April 1, 2010, to March 31, 2015.
The study was approved by the Independent Scientific 
Advisory Committee for the Medicines and Healthcare 
products Regulatory Agency (protocol 16_022).
Procedures
We identified physical and mental health conditions that 
involve intensive use of health-care resources. These 
conditions included those from the quality and outcomes 
framework,11 a UK general-practice payment-for-perfor-
mance scheme, with modifications for more granular 
South Asian 
(n=155 435)
Black 
(n=98 815)
Mixed 
(n=33 673)
Other 
(n=58 019)
White 
(n=2 666 234)
Unknown 
(n=860 275)
All ethnicities 
(n=3 872 451)
Sex
Female 78 056 (50·2%) 51 943 (52·6%) 17 172 (51·0%) 30 367 (52·3%) 1 422 425 (53·3%) 355 737 (41·4%) 1 955 700 (50·5%)
Male 77 379 (49·8%) 46 872 (47·4%) 16 501 (49·0%) 27 652 (47·7%) 1 243 809 (46·7%) 504 538 (58·6%) 1 916 751 (49·5%)
Age groups, both sexes (years)
0–9 (n=542 337) 32 971 (6·1%) 21 739 (4·0%) 14 653 (2·7%) 9651 (1·8%) 384 691 (70·9%) 78 632 (14·5%) ··
10–19 (n=433 169) 15 811 (3·7%) 13 059 (3·0%) 5101 (1·2%) 7214 (1·7%) 250 517 (57·8%) 141 467 (32·7%) ··
20–29 (n=546 371) 32 198 (5·9%) 14 866 (2·7%) 5273 (1·0%) 11 224 (2·1%) 345 175 (63·2%) 137 635 (25·2%) ··
30–39 (n=546 596) 33 404 (6·1%) 18 203 (3·3%) 3935 (0·7%) 12 055 (2·2%) 347 786 (63·6%) 131 213 (24·0%) ··
40–49 (n=558 963) 17 387 (3·1%) 16 756 (3·0%) 2518 (0·5%) 8206 (1·5%) 365 120 (65·3%) 148 976 (26·7%) ··
50–59 (n=443 489) 11 339 (2·6%) 7593 (1·7%) 1187 (0·3%) 4834 (1·1%) 304 502 (68·7%) 114 034 (25·7%) ··
60–69 (n=379 796) 6638 (1·7%) 3158 (0·8%) 548 (0·1%) 2774 (0·7%) 295 806 (77·9%) 70 872 (18·7%) ··
70–79 (n=244 823) 4237 (1·7%) 2642 (1·1%) 315 (0·1%) 1382 (0·6%) 209 890 (85·7%) 26 357 (10·8%) ··
≥80 (n=176 907) 1450 (0·8%) 799 (0·5%) 143 (0·1%) 679 (0·4%) 162 747 (92·0%) 11 089 (6·3%) ··
All ages (n=3 872 451) 155 435 (4·0%) 98 815 (2·6%) 33 673 (0·9%) 58 019 (1·5%) 2 666 234 (68·9%) 860 275 (22·2%) ··
Table: Number of individuals in each ethnic group in the study population from April 1, 2010, to March 31, 2015, stratified by age and sex 
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phenotypes that reflect distinct pathological pathways—
where applicable—such as type 1 diabetes, type 2 
diabetes, and diabetes (other or unspecified).
The number of finished consultant episodes (the time 
spent by an inpatient under the care of one consultant) 
for all diagnoses in England from April 1, 2014, to 
March 31, 2015, was obtained from inpatient activity 
reports published by NHS Digital.12 Diagnoses were 
coded using three-character or four-character codes from 
the International Classification of Diseases, tenth 
revision (ICD-10). We examined the finished consultant 
episodes for codes in chapters I–XIV and XVI–XVII of 
the ICD-10. We excluded pregnancy-related conditions, 
symptoms, signs, abnormal clinical and laboratory 
findings, and external causes of morbidity and mortality. 
Three-character or four-character ICD-10 codes were 
assigned to specific conditions as agreed between 
clinicians in the team (VK, OB, SS, SH, MH, DN, CAP, 
RTL, RS, and ADH). Conditions with codes that had 
more than 10 000 finished consultant episodes were 
included. If a condition had fewer than 10 000 finished 
consultant episodes but the prevalence was greater than 
0·01% and it was considered to be clinically important by 
our panel, it was included in the study (appendix p 56).
Infections were categorised by organ system and causal 
organism. Chronic infections with long-term sequelae 
included were HIV, chronic viral hepatitis, tuberculosis, 
and rheumatic fever. Acute infections were limited to 
hospital admissions. Obesity was only considered for 
individuals older than 18 years.
Health conditions were harmonised across primary-
care and secondary-care coding systems and organised 
into 16 disease categories corresponding closely to ICD-10 
chapters (appendix pp 2–6).
Phenotyping algorithms defining these conditions 
were based on diagnosis or procedural codes, with the 
additional inclusion of some blood test values or other 
measures—ie, estimated glomerular filtration rate, total 
cholesterol, low-density lipoprotein cholesterol, high-
density lipoprotein cholesterol, triglyceride, or body-
mass index (BMI). Diagnoses and procedures are 
recorded in CPRD with Read codes. ICD-10 diagnosis 
codes and Office of the Population Censuses and Surveys 
Classification of Interventions and Procedures version 4 
(OPCS-4) procedural codes are used in the HES for 
admitted-patient care. Keywords were searched in the 
Read and OPCS-4 dictionaries for each of the selected 
conditions to construct the Read and OPCS-4 codelists. 
Patients were considered to have or have had a specific 
condition if they met the criteria in the algorithm for that 
condition before or during the study period. Algorithms 
and codelists for all identified conditions are available on 
the CALIBER Portal. The algorithms can be downloaded 
in a machine-readable CSV format from the algorithm 
data repository.
Selection of health conditions, algorithm development, 
and codelist construction were done by a panel of clinicians 
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with expertise spanning the range of recorded conditions 
(VK, OB, SH, SS, MH, DN, CAP, RTL, RS, and ADH).
The main outcomes of our study were cumulative 
incidence and period prevalence, stratified by age, 
ethnicity, and sex (male and female), and age at first 
diagnosis.
Ethnicity was grouped into the five categories of the 
2011 UK census—ie, white, mixed, south Asian, black, 
and other (appendix pp 7).9 Patients with missing 
ethnicity or codes belonging to more than one category 
were classified as unknown. Ethnic stratification was 
reported for white, south-Asian, and black populations 
only, as interpretation of mixed and other populations is 
less meaningful when considering disease susceptibility.
Statistical analysis
The age at first recorded diagnosis was the earliest age at 
which the criteria in a phenotyping algorithm for a 
specific condition were met from any source. 
The cumulative incidence between April 1, 2010, and 
March 31, 2015, was calculated by dividing the number of 
incident cases (people with first recorded diagnoses) 
during this time period by the number of people in the 
study population at risk on April 1, 2010. We computed 
the sex-standardised cumulative incidence for 10-year 
age bands (0–9 years, 10–19 years, 20–29 years, 30–39 
years, 40–49 years, 50–59 years, 60–69 years, 70–79 years, 
≥80 years). As we had not estimated the prevalence of 
childhood obesity in this study, we did not calculate the 
cumulative incidence for obesity for those between 
18 years and 20 years of age because we were unable to 
determine the denominator (individuals aged 18 years on 
April 1, 2010, who had not previously been defined as 
obese). Age-specific, sex-specific, and ethnicity-specific 
period prevalences from April 1, 2010, to March 31, 2015, 
were calculated by dividing the number of new and pre-
existing cases by the number of people in the study 
population during this time period. Standardisation was 
applied using the 2013 European Standard Population.13 
The median age (IQR) at which conditions were 
first recorded was determined for patients in the study 
population.
We compared our prevalence estimates with those 
from the GBD study1 and from Barnett and colleagues’ 
study. 2 Prevalence estimates were obtained directly from 
the published article in the case of Barnett and colleagues’ 
study,2 or downloaded from the GBD online results tool14 
in the case of the GBD 2017 study.1
Analyses were done using R (version 3.4.3).
Role of the funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation, report writing, or the 
decision to submit the paper for publication. The corres-
ponding author had full access to all the data in the study 
and had final responsibility for the decision to submit for 
publication.
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Results
We developed case definitions for 308 disease phenotypes 
from 10 819 Read codes, 1932 ICD-10 diagnosis codes, 
670 OPCS-4 procedural codes, and measurements of 
estimated glomerular filtration rate, total cholesterol, low-
density lipoprotein cholesterol, high-density lipoprotein 
cholesterol, triglyceride, and BMI. Cumulative-incidence 
estimates from April 1, 2010, to March 31, 2015, were 
calculated from records of 2 784 138 individuals at the start 
of the study period on April 1, 2010. Period-prevalence 
estimates for the same period and the median age at first 
record were derived from 3 872 451 individuals in the study 
population. 2 666 234 (68·9%) of 3 872 451 individuals were 
white, 860 275 (22·2%) had unknown ethnicity, 155 435 
(4·0%) were of south-Asian ethnicity, 98 815 (2·6%) were 
black, 33 673 (0·9%) had mixed ethnicity, and 58 019 
(1·5%) were of other ethnicity; this ethnicity distribution 
was represented across age and sex subgroups (table).
We identified the most common conditions in each 
phase of life for individuals in the study population 
during the study period (figure 1; appendix pp 8–16 and 
58–60)
The most common childhood conditions in children 
younger than 10 years were dermatitis (cumulative 
incidence 8·23%, 95% CI 8·10–8·37; period prevalence 
33·12%, 32·96–33·27), allergic rhinitis (4·86%, 4·77–4·94; 
6·39%, 6·33–6·46), infections from other or unspecified 
organisms (ie, no record satisfying criteria for bacterial 
diseases, tuberculosis, viral diseases, chronic viral 
hepatitis, HIV, mycoses or parasitic infections 30 days 
before or 30 days after the first event date; 4·63%, 
4·54–4·72; 14·16%, 14·06–14·26), infections of the upper 
respiratory tract (3·94%, 3·86–4·02; 12·09%, 12·00–12·18), 
and asthma (3·81%, 3·73–3·89; 7·98%, 7·90–8·05%; 
figure 1A; appendix pp 8–16 and 58–60).
Acne (cumulative incidence 10·08%, 95% CI 
9·96–10·19; period prevalence 17·20%, 17·07–17·32), 
menorrhagia (5·36%, 5·24–5·48; 8·46%, 8·33–8·58), 
and dysmenorrhoea (4·99%, 4·88–5·10; 9·03%, 
8·90–9·15) were common in individuals aged 10–19 years 
(figure 1B; appendix pp 8–16 and 58–60).
Depression (cumulative incidence 5·56%, 95% CI 
5·47–5·64; period prevalence 15·05%, 14·95–15·15), 
anxiety (4·38%, 4·31–4·46; 11·67%, 11·58–11·76), obesity 
(2·96%, 2·89–3·02; 9·53%, 9·45–9·61), and migraine 
(2·23%, 2·18–2·29; 8·30%, 8·22–8·37) began to emerge 
from young adulthood (ie, individuals aged 20–29 years; 
figure 1C; appendix pp 8–16 and 58–60).
Enthesopathy and synovial disorders (cumulative 
incidence 4·38%, 95% CI 4·31–4·45; period prevalence 
11·21%, 11·12–11·30) and gastro-oesophageal reflux 
disease (2·50%, 2·45–2·55; 6·08%, 6·02–6·15) began to 
feature more prominently in individuals aged 30–39 years 
(figure 1D; appendix pp 8–16 and 58–60).
For individuals aged 40–59, raised total cholesterol 
(cumulative incidence 6·32%, 95% CI 6·24–6·40 [ for the 
40–49 years age range], and 9·79%, 9·66–9·91 [ for the 
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50–59 years age range]; period prevalence 22·05%, 
21·92–22·17 [ for the 40–49 years age range], and 41·72%, 
41·53–41·91 [ for the 50–59 years age range]), hypertension 
(cumulative incidence 4·55%, 4·49–4·62 [ for the 40–49 
years age range], and 8·56%, 8·45–8·66 [ for the 50–59 
years age range]; period prevalence 11·80%, 11·71–11·89 
[ for the 40–49 years age range], and 26·55%, 26·40–26·70 
[ for the 50–59 years age range]), raised low-density 
lipoprotein cholesterol (cumulative incidence 4·39%, 
4·33–4·46 [ for the 40–49 years age range], and 6·64%, 
6·54–6·73 [ for the 50–59 years age range]; period 
prevalence 14·52%, 14·42–14·62 [ for the 40–49 years age 
range], and 27·46%, 27·30–27·61 [ for the 50–59 years age 
range]), and erectile dysfunction (cumulative incidence 
3·34%, 3·26–3·42 [ for the 40–49 years age range], and 
5·86%, 5·75–5·97 [ for the 50–59 years age range]; period 
prevalence 8·14%, 8·04–8·25 [ for the 40–49 years age 
range], and 15·51%, 15·35–15·68 [ for the 50–59 years age 
range]) acquired increased importance (figure 1E–F; 
appendix pp 8–16 and 58–60).
Conditions that gained prominence among individuals 
aged 60–79 years were all cancers (cumulative incidence 
10·44%, 95% CI 10·32–10·56 [ for the 60–69 years age 
range], and 18·34%, 18·13–18·54 [ for the 70–79 years age 
range]; period prevalence 18·63%, 18·50–18·77 [ for the 
60–69 years age range], and 30·02%, 29·80–30·24 [ for the 
70–79 years age range]), cataract (cumulative incidence 
4·85%, 4·77–4·92 [ for the 60–69 years age range], and 
13·73%, 13·56–13·90 [ for the 70–79 years age range]; 
period prevalence 9·46%, 9·36–9·56 [ for the 60–69 years 
age range], and 27·55%, 27·34–27·75 [ for the 70–79 years 
age range]), osteoarthritis (cumulative incidence 9·26%, 
9·14–9·38 [ for the 60–69 years age range], and 12·14%, 
11·96–12·32 [ for the 70–79 years age range]; period 
prevalence 28·68%, 28·51–28·85 [ for the 60–69 years age 
range], and 41·88%, 41·63–42·14 [ for the 70–79 years age 
range]), benign prostatic hyperplasia (cumulative incidence 
6·13%, 6·00–6·26 [ for the 60–69 years age range], and 
9·81%, 9·59–10·03 [ for the 70–79 years age range]; period 
prevalence 16·36%, 16·18–16·54 [ for the 60–69 years age 
range], and 30·99%, 30·66–31·31 [ for the 70–79 years age 
range]), diverticular disease (cumulative incidence 4·74%, 
4·66%–4·81% [ for the 60–69 years age range], and 6·99%, 
6·87–7·10 [ for the 70–79 years age range]; period 
prevalence 9·92%, 9·82–10·02 [ for the 60–69 years age 
range], and 17·17%, 17·00–17·33 [ for the 70–79 years age 
range]), type 2 diabetes (cumulative incidence 3·98%, 
3·90–4·05 [ for the 60–69 years age range], and 4·83%, 
4·73–4·93 [ for the 70–79 years age range]; period 
prevalence 13·23%, 13·11–13·34 [ for the 60–69 years age 
range], and 19·36%, 19·19–19·54 [ for the 70–79 years age 
range]), and deafness (cumulative incidence 3·94%, 
3·87–4·01 [ for the 60–69 years age range], and 6·89%, 
6·77–7·01 [ for the 70–79 years age range]; period prevalence 
12·85%, 12·74–12·96 [ for the 60–69 years age range], and 
20·94%, 20·75–21·12 [ for the 70–79 years age range]; 
figure 1G–H and appendix pp 8–16 and 58–60).
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Atrial fibrillation (cumulative incidence 16·78%, 
95% CI 16·55–17·01; period prevalence 32·29%, 
32·02–32·56), dementia (15·03%, 14·84–15·24; 24·51%, 
24·29–24·74)), acute kidney injury (14·02%, 13·83–14·21; 
16·44%, 16·25–16·63), heart failure (13·04%, 
12·85–13·24; 23·18%, 22·96–23·41), anaemia (other or 
unspecified [not iron-deficiency anaemia, B12-deficiency 
anaemia, folate-deficiency anaemia, thalassaemia, 
thalassaemia trait, sickle cell anaemia, other haemolytic 
anaemia, or aplastic anaemia]; 11·30%, 11·12–11·48; 
21·94%, 21·72–22·16), osteoporosis (6·94%, 6·81–7·08; 
17·94%, 17·76–18·13), chronic kidney disease (6·65%, 
6·50–6·80; 32·09%, 31·83–32·35), hip fracture (6·47%, 
6·34–6·60; 12·43%, 12·27–12·58), and myocardial 
infarction (6·12%, 5·99–6·25; 16·70%, 16·50–16·90) 
contributed sub stantially to the disease burden in 
advanced age (ie, ≥80 years; figure 1I; appendix pp 8–16 
and 58–60).
Age-standardised period-prevalence estimates for the 
308 conditions stratified by sex and ethnicity are provided 
in the appendix (pp 17–26).
We examined the differences in median age of 
diagnosis of the health conditions in the study by 
ethnicity and sex (figure 2–4 and appendix pp 27–37). Our 
ethnicity subanalysis found that white individuals had 
later median age at first record than black or south-Asian 
individuals for 258 (84%) of 308 conditions. Conditions 
with large differences in median age of diagnosis 
between ethnicities included  sepsis (26 years [IQR 0–54] 
for black individuals vs 29 years [0–63] for south-Asian 
individuals vs 66 years [33–80] for white individuals), 
lower respiratory tract infection (30 years [3–51] vs 
31 years [2–62] vs 65 years [33–80]), hip fracture (49 years 
[30–78] vs 72 years [47–81] vs 80 years [69–87]), encephalitis 
(18 years [6–43] vs 23 years [7–48] vs 48 years [23–69]), 
immunodeficiency (32 years [10–43] vs 11 years [2–41] vs 
39 years [8–65]), urinary tract infection (45 years [28–71] 
vs 45 years [26–70] vs 73 years [47–84]), seborrheic 
dermatitis (11 years [2–33] vs 19 years [2–34] vs 37 years 
[15–58]), and sleep apnoea (29 years (4–45] vs 38 years 
[7–51] vs 49 years [36–60]).
In our subanalysis of differences between sexes, we 
found that women were diagnosed earlier than men with 
tubulointerstitial nephritis (median age 30 years 
[IQR 22–48] for women vs 53 years [35–68] for men), 
iron-deficiency anaemia (45 years [31–67] vs 66 years 
[44–77]), anaemia (other or unspecified; 48 years [32–74] 
vs 69 years [53–79]), chronic cystitis (53 years [36–67] vs 
69 years [59–77]), urinary incontinence (51 years [40–66] 
vs 66 years [41–78]), secondary thrombocytopenia 
(48 years [30–69] vs 62 years [43–74]), fungal infection 
(50 years [26–75] vs 64 years [42–77]), and obstructive or 
reflux uropathy (43 years [20–67] vs 54 years [21–72]).
Men or boys were diagnosed at younger ages than 
women or girls with wrist fracture (median age 54 years 
[15–69] for women or girls vs 15 years [11–32] for men or 
boys), anorectal prolapse (64 years [46–77] vs 47 years 
[6–65]), gout (69 years [58–78] vs 56 years [45–67]), 
hypertrophic cardiomyopathy (65 years [51–76] vs 53 years 
[40–64]), spondylolisthesis (63 years [49–74] vs 51 years 
[37–66]), asthma (25 years [9–45] vs 13 years [5–37]), and 
urticaria (31 years [12–49] vs 19 years [6–43]).
We compared the study design and characteristics of 
our study with those of the GBD 2017 study1 and of 
Barnett and colleagues’ study2 (appendix p 38). Prevalence 
values for 112 out of the 308 conditions in our study were 
previously reported by either one or the other study.1,2 We 
compared the prevalence estimates between the three 
studies for the 112 overlapping conditions and reported 
the prevalence estimates for non-overlapping conditions 
by disease category (appendix pp 39–41 and 42–55).
Our study included more long-term conditions than the 
GBD study, which concentrated on infections, injuries, 
maternal conditions, and oral diseases (figure 5, appendix 
pp 42–55). We also reported on a wider range of neoplasms, 
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Figure 1: Sex-standardised cumulative incidence (%) of the top 50 diseases and all cancers between April 1, 2010, 
and March 31, 2015, for individuals aged 1–9 years (A), 10–19 years (B), 20–29 years (C), 30–39 years (D), 
40–49 years (E), 50–59 years (F), 60–69 years (G), 70–79 years (H), or 80 years or more (I) on April 1, 2010
AKI=acute kidney injury. BPH=benign prostatic hyperplasia. CIN=cervical intraepithelial neoplasia. CKD=chronic 
kidney disease. COPD=chronic obstructive pulmonary disease. GORD=gastro-oesophageal reflux disease. 
HDLC=high-density lipoprotein cholesterol. IBS=irritable bowel syndrome. ID=infectious disease. LDLC=low-density 
lipoprotein cholesterol. LRTI=lower respiratory tract infection. PCOS=polycystic ovary syndrome. PID=pelvic 
inflammatory disease. T1D=type 1 diabetes. T2D=type 2 diabetes. TIA=transient ischaemic attack. URTI=upper 
respiratory tract infection. UTI=urinary tract infection. 
See Online for appendix
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com/spiros/chronological-map-
phenotypes
Articles
www.thelancet.com/digital-health   Vol 1   June 2019 e71
including secondary malignancies and benign neoplasms, 
and mental health conditions such as personality disorder 
and obsessive-compulsive disorder, whereas the GBD 
study presented results for subtypes of substance use 
disorders, leukaemia, and liver cancer. 11 of the conditions 
reported by Barnett and colleagues2 were not directly 
comparable with the disease phenotypes reported here 
(appendix pp 42–55).
Prevalence estimates for most overlapping conditions 
were similar between this study and the GBD and Barnett 
and colleagues’ studies (appendix pp 39–41), with the 
absolute difference in prevalence estimates between 
studies smaller than 2·5 percentage points for 71 of the 
104 conditions included in both the GBD1 and this study, 
and for 19 of 29 conditions included in both this and the 
Barnett and colleagues’ studies.2 The widest differences 
in prevalence estimates between our study and the GBD 
or Barnett and colleagues’ studies1,2 were for dermatitis 
(25·44% in our study vs not applicable (NA) in Barnett 
and colleagues’ study2 vs 6·82% in the GBD study1), 
migraine (6·97% vs 0·60%2 vs 20·65%1), depression 
(17·44% vs 8·20%2 vs 4·36%1), deafness (8·86% vs 3·40%2 
vs 19·12%1), anxiety (12·96% vs 3·20%2 vs 4·43%1), 
tuberculosis (0·68% vs NA2 vs 9·02%1), abdominal hernia 
(7·57% vs NA2 vs 0·38%1), asthma (14·99% vs 6·00%2 vs 
8·37%1), and blindness (1·20% vs 0·50%2 vs 7·05%1).
Discussion
We introduced the first chronological map of human 
health, with cumulative-incidence estimates, period-
prevalence estimates, and median age at first record for 
308 conditions from a single, large, clinically representative 
study population, stratified by age, sex, and ethnicity.
Although this chronological map reflects the burden of 
health conditions in England, it is likely to be relevant to 
other high-income countries with similar age and sex 
profiles. The findings complement the GBD reports, 
which have a wide geographical remit and hence 
encompass low-income, middle-income, and high-income 
countries. Prevalence estimates for some long-term 
conditions common in the NHS—such as hypertension, 
dyslipidaemia, irritable bowel syndrome, and thyroid 
disorders— were not included in GBD 2017.1 Our coverage 
of conditions was both wider (spanning both primary and 
secondary care) and more granular than in the seminal 
Scottish primary-care study by Barnett and colleagues.2 
We classified cancers by major organ system, and 
subcategorised coronary heart disease into stable angina, 
myocardial infarction, unstable angina, and coronary 
heart disease not otherwise specified.
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Figure 2: Median age at first record for diseases with median age of diagnosis 
at or before 40 years, stratified by sex (A) and ethnicity (B)
CIN=cervical intraepithelial neoplasia. IBS=irritable bowel syndrome. 
ID=infectious disease. OCD=obsessive-compulsive disorder. PCOS=polycystic 
ovary syndrome. PID=pelvic inflammatory disease. T1D=type 1 diabetes. 
URTI=upper respiratory tract infection. 
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Frequency estimates for health conditions in this study 
convey the actual clinical experience of individuals in the 
NHS as documented in their EHRs. Prevalence estimates 
in the established medical literature vary widely and 
depend on multiple factors, including case definition, 
methodology, study sample, and time of measurement. 
Many disease-prevalence estimates are based on sparse 
sample sets from dated clinical studies, or surveys not 
representative of the general population. GBD 20171 
collated disease-distribution estimates from various 
sources including published literature, with renewed 
analysis of publicly available data and estimated 
prevalence with statistical models, whereas Barnett and 
colleagues2 reported point prevalence values based on 
EHRs from Scottish general-practice data in 2007. The 
period-prevalence estimates in this study are expected to 
be higher than the point-prevalence measures reported in 
the GBD or Barnett and colleagues’ studies.1,2 This is 
because we included all individuals who had ever been 
recorded with a condition, not just individuals presumed 
to have the condition at the time of analysis. Our period-
prevalence calculation included people who had died 
during the study period; hence, conditions more common 
in those who died could have higher estimates in this 
report than in previous reports.1,2 Another potential 
reason for higher prevalence estimates in this report than 
in Barnett and colleagues’ study2 is the inclusion of 
secondary-care data in our case definitions. Comparison 
between these three large studies illustrates the 
similarities and differences in estimates using different 
methodologies, and allows the reader to select the method 
most relevant for their objectives. We reviewed disease 
frequency estimates from other published studies for 
conditions with the largest disparities between this study 
and the GBD or Barnett studies in the appendix (p 1).
Our age-stratified analysis enabled us to chronicle the 
passage of health conditions across the lifecourse. 
Hospital-admitted infections affected individuals at the 
extremes of life (<10 years and ≥80 years). Atopic 
conditions were common in childhood (<10 years). 
Mental health disorders were most prevalent from early 
adulthood (≥20 years). Menstrual disorders and migraine 
afflicted women of childbearing age (20–49 years). 
Metabolic conditions, particularly dyslipidaemias and 
obesity, together with hypertension, increased in 
prevalence from middle age (≥40 years). Cardiovascular 
diseases emerged later in life (≥60 years), following the 
surge in metabolic conditions in middle-age. Degenerative 
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Figure 3: Median age at first record for diseases with median age of diagnosis 
between 40–60 years, stratified by sex (A) and ethnicity (B)
For the key for the disease categories refer to figure 2. 
GORD=gastro-oesophageal reflux disease. HDLC=high-density lipoprotein 
cholesterol. HOCM=hypertrophic obstructive cardiomyopathy. 
ID=infectious disease. LDLC=low-density lipoprotein cholesterol. 
NOS=not otherwise specified. PE=pulmonary embolism. 
SVT=supraventricular tachycardia. VTE=venous thromboembolism.
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conditions involving the sense organs, musculoskeletal, 
genitourinary, and neurological systems were prominent 
in older individuals (≥80 years).
This is the first study to systematically document the 
age of diagnosis for hundreds of health conditions 
contemporaneously. Age of first recorded diagnosis 
encapsulates information regarding the age of onset and 
diagnosis, consultation patterns, and diagnostic and 
recording practices. It might also reveal different 
subtypes of disease according to sex and ethnicity.
The median age at first record was later in white 
individuals than in other ethnicities for 258 (84%) of the 
308 conditions. Similar results have previously been 
reported for cancers.15 We found no significant diff erences 
between ethnicities in age-specific prevalence for acute 
infections, for which discrepancies in the age at first record 
between ethnicities were wide. Therefore, the later age at 
diagnosis for acute infections, and potentially other 
conditions, could be attributed to the higher proportion of 
older people in the white population than in other 
ethnicities. Other reasons for the younger ages at diagnosis 
of ethnic minorities could be a combination of genetic pre-
disposition, socioeconomic status, or culturally determined 
health beliefs and practices.
Different pathological pathways might also be 
responsible for disorders affecting different ethnicities at 
different ages. Black individuals were diagnosed earlier 
with sleep apnoea than white individuals. This finding 
was consistent with our prevalence estimates, which 
identified a higher prevalence among black boys (aged 
<20 years) and white men older than 30 years. Sleep 
apnoea is usually associated with adenotonsillar 
hypertrophy in children,16 whereas in adults the main 
contributing factors are obesity, male sex, and age.17
Distinct disease mechanisms could also give rise to 
disparities in age of diagnosis between the sexes. Up to 
the age of 40 years, wrist fractures were more common in 
men and boys, but after this age, the incidence was higher 
in women. This difference could be attributed to higher-
risk physical activities in young men or boys than in 
women or girls, and to decreased bone mineral density in 
older women (≥40 years). Male individuals were diagnosed 
with asthma at a younger age than female individuals, 
with earlier age at first record and higher cumulative 
incidence in boys younger than 10 years, whereas more 
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Figure 4: Median age at first record for diseases with median age of diagnosis 
after 60 years, stratified by sex (A) and ethnicity (B)
For the key for the disease categories refer to figure 2. AAA=abdominal aortic 
aneurysm. AKI=acute kidney injury. AV=atrioventricular. BPH=benign prostatic 
hyperplasia. CHD=coronary heart disease. CKD=chronic kidney disease. 
COPD=chronic obstructive pulmonary disease. ID=infectious disease. LBBB=left 
bundle branch block. LRTI=lower respiratory-tract infection. MGUS= Monoclonal 
gammopathy of undetermined significance. NOS=not otherwise specified. 
PAD=peripheral arterial disease. RBBB=right bundle branch block. 
SIADH=syndrome of inappropriate antidiuretic hormone secretion. T2D=type 2 
diabetes. TIA=transient ischaemic attack. UTI=urinary tract infection. 
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women and girls were diagnosed with asthma after this 
age. This pattern of early-onset asthma in men or boys but 
late-onset in women or girls has been reported 
elsewhere.18,19 Asthma is a heterogeneous disease, and 
early-onset asthma has been related to atopy and has 
substantial genetic susceptibility, whereas late-onset 
asthma tends to be non-allergic and induced by 
environmental and hormonal triggers.18,19 Tubulo-
interstitial nephritis was diagnosed earlier in women than 
in men. An Australian study found an increase in acute 
interstitial nephritis in young women, which they 
attributed to immune-mediated conditions or analgesic 
nephropathy.20
Potential beneficiaries from this study include individual 
patients, patient groups, medical charities, practising 
clinicians (in primary and secondary care), health-care 
providers, public health organisations, policy makers, and 
medical researchers both in academia and industry, 
including those involved in drug development and 
evaluation.
Knowing the age-specific and sex-specific incidence 
and prevalence could help patients gain perspective into 
their conditions. Patient organisations can use these data 
for awareness campaigns and to support fundraising.
Our chronological map can guide clinicians assessing 
individual patients on the likelihood of possible diagnoses 
on the basis of their frequency distribution in the general 
population at different ages. It could also be the first step 
towards the creation of decision-support tools from EHRs 
using artificial intelligence.21
Age-specific incidence data on a wide range of 
preventable health conditions such as those presented in 
this Article are essential to realise the ambitions of the 
NHS Five Year Forward View22 and the Life Sciences 
Industrial Strategy,23 which have prioritised disease 
prevention and the development of new technologies to 
achieve this goal.
Commissioners of clinical services can use the findings 
from this study to inform budget allocation. The high 
prevalence of mental health, metabolic syndrome, 
musculoskeletal, and gynaecological conditions identified 
in this study highlights health-care delivery needs for these 
conditions. The incidence and prevalence of dementia will 
rise as the population ages. This will require not only 
effective drugs to prevent the onset of this condition, but 
also adequate social services to maintain the quality of life 
for affected individuals for as long as possible.
Our analysis lends support to calls for workforce 
expansion in key specialties.24 Adequate staffing is 
urgently needed to treat highly prevalent conditions at 
different stages of the lifecourse, such as mental health 
and gynaecological disorders from young adulthood to 
middle age, and musculoskeletal, neurodegenerative, 
and eye conditions in later life.
High degrees of disparity between research funding 
and disease burden have been shown in mental health, 
musculoskeletal, and cardiovascular conditions.25 Our 
findings reinforce the need for increased research 
investment into these conditions.
Delineating unmet health-care needs is crucial when 
planning and prioritising the initiation of new drug-
development programmes. Understanding when specific 
disease endpoints are most likely to occur, and in which 
individuals, is essential in designing and planning 
clinical trials.
By providing the case definitions for hundreds of 
conditions and their median age at diagnosis, we are laying 
the foundation for future studies into multi morbidity and 
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Figure 5: Number of diseases with reported case definitions and prevalences in the UK for each disease 
category from this study (A) or the Global Burden of Disease 2017 study1 (B)
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ageing-related diseases using EHRs. The need for this 
research has been highlighted in a 2018 report published 
by the Academy of Medical Sciences.26
The phenotyping algorithms in our platform can also be 
applied to EHRs linked to research-based cohort studies to 
provide disease-phenotype enrichment to support large-
scale genetic-association studies.27–29 This integration of 
EHRs with genetic and other biomedical data enables a 
systems approach to the pathophysiology of disease. For 
example, phenome-wide association studies based on 
hospital EHRs are helping to identify diseases with 
common biological mechanisms.30 Collectively, these 
methods could unlock new opportunities for drug target 
discovery and repositioning.31
The main limitation in this study is its dependence on 
the accuracy of data recording. Although general 
practitioners directly enter codes into patients’ EHRs 
during primary-care consultations, in secondary care, 
records are primarily paper-based and trained coders 
extract information from handwritten notes to allocate 
diagnoses and procedural codes for a hospital episode, 
during which process vital information could be 
misinterpreted and incorrectly reported. We expect the 
accuracy of secondary-care EHRs to improve with 
widespread adoption by clinicians of computerised 
hospital medical records.
Conditions might be under-represented in EHRs 
compared with surveys, as patients with mild to moderate 
symptoms might not present to health-care services. 
However, surveys are susceptible to non-response, 
response, selection, and volunteer biases, so the results 
might not be generalisable to the wider population.32 
Asymptomatic cases can also lead to underestimates 
in conditions in which diagnosis requires clinical 
examination or investigations. Although clinical studies 
might detect asymptomatic cases, they are seldom 
representative of the general population.
A time-lag might occur between disease onset and 
the age of first record because of delays in clinical 
manifestation, presentation to the doctor, and documen-
tation of the condition in the patients’ records. Age at 
first diagnosis, therefore, might not reflect the actual age 
of onset, especially for diseases with a long subclinical 
phase.
The NHS Health Checks programme33 began in 2009 
with the aim of reducing cardiovascular-disease risks and 
events. This has led to increased lipid profiling, blood 
pressure and BMI measurements in patients aged 
40–74 years. Although this might have biased our 
estimation of incidence, prevalence, and age of first 
recorded diagnosis of dyslipidaemia towards middle-aged 
patients, it nevertheless allowed us to capture all relevant 
clinical measurements in a large population-based study, 
as opposed to relying on surveys or statistical estimations.
NHS England offers a range of other screening tests to 
different sections of the population, depending on their 
risk of developing specific conditions. These programmes 
aim to detect early signs of disease in asymptomatic 
individuals. Neonates are screened for rare metabolic 
conditions, including cystic fibrosis and sickle-cell 
disease. Pregnant women are screened for fetal 
anomalies, HIV, syphilis, hepatitis B, sickle-cell disease, 
and thalassaemia. Patients with diabetes are screened for 
eye complications. Cervical screening is offered to 
women aged 25–64 years and breast screening is offered 
to women aged 50–70 years. Bowel-cancer screening is 
offered to individuals aged 55 years in some parts of 
England and 60–74 years throughout England, and 
screening for abdominal aortic aneurysm is offered to 
men aged 65 years. The eligibility criteria for screening, 
together with differing response rates within the invited 
population might bias the generalisability of prevalence 
estimates based on EHRs. Nevertheless, these screening 
programmes allow more cases to be identified from 
EHRs than other study samples, which would not be 
devoid of biases in any case.
We have identified anomalies in the records due to 
inaccurate coding for rare conditions and disorders with 
asymptomatic or carrier states. Autosomal recessive 
disorders such as thalassaemia and cystic fibrosis had 
median ages at first record of 29 years and 31 years, later 
than would have been anticipated. These conditions had 
a bimodal distribution of age at first record, with a 
first peak in early childhood and the second peak at child-
bearing age (appendix p 61). One explanation for these 
results could be that patients considering parenthood 
were erroneously coded as having these conditions after 
genetic screening tests revealed that they were hetero-
zygous carriers. Another explanation is that mothers of 
neonates with these conditions were coded in lieu of 
their affected children who had not yet been registered 
with a general practice. Researchers using EHR data for 
these conditions should employ quality-control measures 
before analysis.
Caution needs to be exercised when interpreting the 
data for HIV, chronic hepatitis, and other sexually 
transmitted infections. In the UK, most consultations 
involving sexually transmitted infections are diagnosed 
and treated at sexual health service centres.34 The records 
from these services are not linked to primary or 
secondary care for reasons of confidentiality. Therefore, 
these conditions are under-reported in the CPRD linked 
dataset.
As the population ages and multimorbidity becomes 
more prevalent, clinicians, health-care planners, policy 
makers, and researchers need to know which sections of 
the population are vulnerable to which health conditions 
at which ages to prevent, detect, and treat these 
conditions effectively. We have generated a compendium 
of health conditions consisting of a comprehensive 
reference of case-definition algorithms and frequency-
distribution patterns, together with a chronological 
map of human health conditions over the lifecourse to 
address this need. 
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